MS-DRG 791

Principal Diagnosis - Pdx

• T42.4X5A Adverse effect of benzodiazepines, initial encounter
• T42.5X5A Adverse effect of mixed antiepileptics, initial encounter
• T42.6X5A Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
• T42.75XA Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
• T42.8X5A Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
• T43.015A Adverse effect of tricyclic antidepressants, initial encounter
• T43.025A Adverse effect of tetracyclic antidepressants, initial encounter
• T43.1X5A Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
• T43.205A Adverse effect of unspecified antidepressants, initial encounter
• T43.215A Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
• T43.225A Adverse effect of selective serotonin reuptake inhibitors, initial encounter
• T43.295A Adverse effect of other antidepressants, initial encounter
• T43.3X5A Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
• T43.4X5A Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
• T43.505A Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter
• T43.595A Adverse effect of other antipsychotics and neuroleptics, initial encounter
• T43.605A Adverse effect of unspecified psychostimulants, initial encounter
• T43.615A Adverse effect of caffeine, initial encounter
• T43.625A Adverse effect of amphetamines, initial encounter
• T43.635A Adverse effect of methylphenidate, initial encounter
• T43.655A Adverse effect of methamphetamines, initial encounter
• T43.695A Adverse effect of other psychostimulants, initial encounter
• T43.8X5A Adverse effect of other psychotropic drugs, initial encounter
• T43.95XA Adverse effect of unspecified psychotropic drug, initial encounter
• T44.0X5A Adverse effect of anticholinesterase agents, initial encounter
• T44.1X5A Adverse effect of other parasympathomimetics [cholinergics], initial encounter
• T44.2X5A Adverse effect of ganglionic blocking drugs, initial encounter
• T44.3X5A Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
• T44.4X5A Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
• T44.5X5A Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
• T44.6X5A Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
• T44.7X5A Adverse effect of beta-adrenoreceptor antagonists, initial encounter
• T44.8X5A Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
• T44.905A Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
• T44.995A Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
• T45.0X5A Adverse effect of antiallergic and antiemetic drugs, initial encounter
• T45.1X5A Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
• T45.2X5A Adverse effect of vitamins, initial encounter
• T45.3X5A Adverse effect of enzymes, initial encounter
• T45.4X5A Adverse effect of iron and its compounds, initial encounter
• T45.515A Adverse effect of anticoagulants, initial encounter
• T45.525A Adverse effect of antithrombotic drugs, initial encounter
• T45.605A Adverse effect of unspecified fibrinolysis-affecting drugs, initial encounter
• T45.615A Adverse effect of thrombolytic drugs, initial encounter
• T45.625A Adverse effect of hemostatic drug, initial encounter
• T45.695A Adverse effect of other fibrinolysis-affecting drugs, initial encounter
• T45.7X5A Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
• T45.8X5A Adverse effect of other primarily systemic and hematological agents, initial encounter
• T45.95XA Adverse effect of unspecified primarily systemic and hematological agent, initial encounter
• T46.0X5A Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
• T46.1X5A Adverse effect of calcium-channel blockers, initial encounter
• T46.2X5A Adverse effect of other antidysrhythmic drugs, initial encounter
• T46.3X5A Adverse effect of coronary vasodilators, initial encounter
• T46.4X5A Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
• T46.5X5A Adverse effect of other antihypertensive drugs, initial encounter
• T46.6X5A Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
• T46.7X5A Adverse effect of peripheral vasodilators, initial encounter
• T46.8X5A Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter
• T46.905A Adverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounter
• T46.995A Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter
• T47.0X5A Adverse effect of histamine H2-receptor blockers, initial encounter
• T47.1X5A Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
• T47.2X5A Adverse effect of stimulant laxatives, initial encounter
• T47.3X5A Adverse effect of saline and osmotic laxatives, initial encounter
• T47.4X5A Adverse effect of other laxatives, initial encounter
• T47.5X5A Adverse effect of digestants, initial encounter
• T47.6X5A Adverse effect of antidiarrheal drugs, initial encounter
• T47.7X5A Adverse effect of emetics, initial encounter
• T47.8X5A Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter
• T47.95XA Adverse effect of unspecified agents primarily affecting the gastrointestinal system, initial encounter
• T48.0X5A Adverse effect of oxytocic drugs, initial encounter
• T48.1X5A Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
• T48.205A Adverse effect of unspecified drugs acting on muscles, initial encounter
• T48.295A Adverse effect of other drugs acting on muscles, initial encounter
• T48.3X5A Adverse effect of antitussives, initial encounter
• T48.4X5A Adverse effect of expectorants, initial encounter
• T48.5X5A Adverse effect of other anti-common-cold drugs, initial encounter
• T48.6X5A Adverse effect of antiasthmatics, initial encounter
• T48.905A Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter
• T48.995A Adverse effect of other agents primarily acting on the respiratory system, initial encounter
• T49.0X5A Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
• T49.1X5A Adverse effect of antipruritics, initial encounter
• T49.2X5A Adverse effect of local astringents and local detergents, initial encounter
• T49.3X5A Adverse effect of emollients, demulcents and protectants, initial encounter
• T49.4X5A Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter
• T49.5X5A Adverse effect of ophthalmological drugs and preparations, initial encounter
• T49.6X5A Adverse effect of otorhinolaryngological drugs and preparations, initial encounter
• T49.7X5A Adverse effect of dental drugs, topically applied, initial encounter
• T49.8X5A Adverse effect of other topical agents, initial encounter
• T49.95XA Adverse effect of unspecified topical agent, initial encounter
• T50.0X5A Adverse effect of mineralocorticoids and their antagonists, initial encounter
• T50.1X5A Adverse effect of loop [high-ceiling] diuretics, initial encounter
• T50.2X5A Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
• T50.3X5A Adverse effect of electrolytic, caloric and water-balance agents, initial encounter
• T50.4X5A Adverse effect of drugs affecting uric acid metabolism, initial encounter
• T50.5X5A Adverse effect of appetite depressants, initial encounter
• T50.6X5A Adverse effect of antidotes and chelating agents, initial encounter
• T50.7X5A Adverse effect of analeptics and opioid receptor antagonists, initial encounter
• T50.8X5A Adverse effect of diagnostic agents, initial encounter
• T50.905A Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter